Embedded Files
Research experience (after PhD): > 26 years
Research Area - Protein Biopharmaceuticals
It is evident now that, in coming decade, the domestic as well as the international market for protein biopharmaceuticals will grow rapidly and will expand its share of the entire pharmaceuticals market. Also, there is a dire need to develop protein biopharmaceuticals to lower the import burden and to make our Nation self-reliant. This may also lower the cost and make these drugs available and more affordable to Jan-Manas (common man). My laboratory is involved in the development of novel Protein Biopharmaceuticals (Antibody-based products; and other biopharmaceuticals) and the details of my current research programs are summarized below:
Programme 1 – Antibody-Based Products
Our antibody engineering program focuses on developing next-generation PolyBodies™ and ConBodies™, with BiSpekDAb™ as a lead and most advanced molecule. BiSpekDAb™ is a bispecific antibody targeting IL-23 and TNF-α and has shown strong anti-inflammatory efficacy in animal models of asthma, stroke, and other inflammatory conditions. It is currently undergoing detailed IND Enabling, non-GLP preclinical characterization and is protected by patents #13, 16.
Alongside this front-runner, we are also advancing PolyBodies™ such as BiSpekDAb-2, PvTDAb (patents #9, 12), and PhotoBodies (patents #18), as well as ConBodies™ including μBodies™, BsTCE, ChemoBodies, RadioBodies, and PainBodies (patents # 15, 17, 20-22, 24). These molecules collectively represent a broad antibody platform aimed at providing multi-target engagement, enhanced potency, and precision delivery of therapeutic payloads.
Programme 2 – Enzyme- and Protein-Based Biopharmaceuticals
Beyond antibody-based therapeutics, we are advancing a focused set of engineered enzymes and peptides with applications in oncology, nerve-agent detoxification, inflammation control, and organophosphate decontamination.
In the peptide space, Neuro-E™ (patents #2, 10), an engineered apolipoprotein-E mimetic peptide, demonstrates strong anti-inflammatory and neuroprotective effects across pulmonary, cardiac, and neurological models, while NGOBLOKER™ (patents #14), an engineered endostatin molecule, has shown desirable anti-angiogenic activity in the Chick CAM model. Additionally, OPHE (patents #24), a nerve-agent neutralizing polypeptide, forms an important part of our detoxification pipeline and complements the enzymatic and peptide-based strategies being developed within this category.
LBURGINAZE™ (patents #6, 8), an engineered human arginase 1 with improved pharmacokinetic properties, shows strong anti-cancer activity and is being developed for liver and pancreatic cancers.
LBUPON™(patents #1, 7, 11, 19), an engineered paraoxonase 1 enzyme, exhibits potent nerve-agent neutralizing activity and enhanced in vivo stability, and is undergoing detailed characterization in collaboration with DRDE (Gwalior) and IRBA (France).
We are also developing a SsoPox-based nanobiocatalyst (patents #3, 5) platform for environmentally safe organophosphate degradation through enzyme immobilization on reusable nanomaterials.
Page updated
Google Sites
Report abuse